Sanofi
-
Sanofi chooses Burgopak slider design for heartburn treatment
Sanofi has chosen the award-winning Burgopak slider design for its heartburn treatment, Maalox Plus, which was launched into the Italian market this year.
Sanofi | 31 October 2011
-
Sanofi appoints David Meeker Chief Executive Officer of Genzyme
Christopher A Viehbacher will retain the position of Chairman, Genzyme.
Sanofi | 24 October 2011
-
Investigational oral MS therapy significantly reduced relapse rate
Findings from two-year phase 3 trial published in New England Journal of Medicine.
Sanofi | 06 October 2011
-
Sanofi Pasteur acquires exclusive, worldwide license for acne vaccine and treatment
Pre-clinical vaccine was developed by researchers at the University of California, San Diego.
Sanofi | 21 September 2011
-
Sanofi Pasteur donates vaccine strain used for polio eradication to WHO
Vaccine strain used in the production of oral polio vaccines against type 3 poliovirus.
Sanofi | 20 September 2011
-
Sanofi appoints Chief Strategy Officer
Sanofi announces the appointment of Dr David-Alexandre Gros as Chief Strategy Officer of Sanofi effective September 1, 2011. He will report to Christopher A Viehbacher, Chief Executive Officer, and will join the Group Executive Committee. He will be …
Sanofi | 28 July 2011
-
Sanofi provides updates on Genzyme product supply
Since the beginning of the year, Genzyme has been able to supply Cerezyme(imiglucerase for injection) to patients globally at normal dosing levels and has maintained consistent supply of Fabrazyme (algalsidase beta) to current patients at a reduced d…
Sanofi | 28 July 2011
-
Sanofi appoints Senior Vice President, Global Services
Sanofi announces the appointment of Greg Irace, currently President and CEO of Sanofi’s US operations, to the newly created role of Senior Vice President, Global Services. In his new role, Greg will lead the Global Information Systems function, be …
Sanofi | 22 July 2011
-
Rib-X, Sanofi sign research collaboration agreement on antibiotics
Novel technology targets bacterial ribosomes creating an entirely new class of antibiotic therapeutics.
Sanofi | 11 July 2011
-
Sanofi, Rib-X sign research collaboration agreement on antibiotics
Sanofi announced the signing of an exclusive worldwide research collaboration agreement and option for license with Rib-X Pharmaceuticals Inc for novel classes of antibiotics resulting from Rib-X's RX-04 program for the treatment of resistant Gram-po…
Sanofi | 01 July 2011
